In the era of immunochemotherapy and approval for HER2-negative advanced gastric cancer as first-line therapy, there is only a general consensus that a combination of chemotherapy plus anti-PD-1/PD-L1 antibodies should be used for gastric cancer patients with CPS ≥ 5. The gene discussed is ERBB2; the disease is gastric cancer.